AI drug discovery in 2026: faster hypotheses, but biology still kingmaker 

AI is helping narrow the search space 

One of AI’s clearest strengths is deciding where to look first. 

Recent reviews describe how AI can integrate multi-omics data, biological networks, and related literature-derived knowledge to connect disease biology with candidate targets more efficiently than traditional linear workflows. That matters because the starting problem is enormous: drug development still takes 12–15 years, costs about $2.6 billion on average, and proceeds against a searchable chemical space often described in the order of 10⁶⁰–10¹⁰⁰ molecules.^1,2,4 

In that context, better triage is already meaningful progress. AI tools do not eliminate uncertainty, but can reduce the number of targets, compounds, and design paths that need to be pursued experimentally. 

Generative models are powerful, but they do not validate themselves 

Generative AI has become one of the most visible parts of the drug discovery conversation. Models can propose new molecular structures, optimize across multiple properties, and support de novo design workflows for small molecules and other modalities.^2–4 

AI-generated compounds may still prove impractical to synthesize, biologically inactive, or have unexpected behavior outside the training conditions used to build the model. The same caution applies to docking and virtual screening: AI-based methods are improving quickly, yet peer-reviewed reviews still note that deep learning approaches do not consistently outperform physics-based methods in all settings, especially where receptor flexibility and physical realism matter.^2,4 

While AI can improve which ideas move forward, it does not by itself establish target engagement, mechanism, or translational relevance. 

The real gap is biological confirmation 

AI is becoming better at proposing plausible answers to questions like: Which target looks disease-relevant? Which scaffold is worth pursuing? Which compound is most likely to balance potency and developability? However, such answers remain hypothetical. Even strong models depend on the quality of the training data, model assumptions, and the degree to which new biology resembles the data the system has already seen. Reviews of AI in drug discovery continue to highlight sparse labeled data, noisy real-world inputs, overfitting, and interpretability as persistent limitations.^1,2,3 

That means the bottleneck is shifting. The challenge is often no longer generating enough hypotheses. It is determining, quickly and convincingly, which of those hypotheses survive contact with real biological systems. 

Where CETSA fits alongside AI 

If AI is strongest at prioritizing what to test, then CETSA can help answer one of the questions AI cannot settle on its own: is the target being engaged in a biologically relevant context? In practical terms, this makes CETSA a natural complement to AI-driven discovery workflows. AI can help reduce the search space; CETSA-based target engagement data can help determine whether the shortlisted compounds are performing as expected in cells or tissues. 

That combination is especially relevant because literature increasingly frames AI as an accelerator for target discovery, molecular generation, and prediction, while also emphasizing the continuing need for mechanistic understanding and high-quality downstream testing. Used in parallel, AI and CETSA can play distinct but complementary roles: one improves prioritization, the other strengthens biological confidence.^1,2,4 

Conclusion 

AI in 2026 is improving the front end of drug discovery more clearly but it is yet to prove itself in clinical outcomes. 

It is getting easier to generate candidates, connect data, and prioritize. It is much less clear that AI alone has solved the harder downstream problems of mechanism, translatability, and clinical success. That is why experimental systems remain central, not secondary, to modern discovery.^2,4 

For teams working under real time and resource constraints, the opportunity is not to choose between AI and experiment. It is to connect them more intelligently. AI can help identify what deserves attention. CETSA can help show whether those computational predictions translate into meaningful target engagement in biology. That is not the whole answer to drug discovery, but it is a practical way to close one of the most important gaps in today’s AI-enabled workflows.